
Immunocore Holdings (IMCR) Stock Forecast & Price Target
Immunocore Holdings (IMCR) Analyst Ratings
Bulls say
Immunocore Holdings PLC has established a positive growth trajectory through its ImmTAX platform, which underpins a robust pipeline targeting multiple therapeutic areas including oncology, infectious diseases, and autoimmune disorders. The company's lead product, KIMMTRAK, has demonstrated strong market performance by surpassing sales expectations in 12 out of 14 quarters since its FDA and EMA approvals in early 2022, indicating solid demand and acceptance in the market. While US market penetration is anticipated to plateau at 68% by mid-2025, growth prospects are supported by increased treatment durations and potential international launches, bolstering the company’s long-term outlook.
Bears say
The financial outlook for Immunocore Holdings appears negative due to disappointing clinical trial results for its key product, KIMMTRAK, which reported low overall response rates of 11% in cutaneous melanoma and 6% in ovarian cancer, failing to meet market expectations. Additionally, the company faces significant competitive pressure from emerging therapies, such as IDYA's darovasertib, which could negatively impact KIMMTRAK's market potential in the HLA-A2+ metastatic uveal melanoma segment. These factors combined suggest a challenging environment for Immunocore Holdings as it attempts to navigate a competitive landscape while depending on underperforming trial data.
This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.
Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction
Start investing in Immunocore Holdings (IMCR)
Order type
Buy in
Order amount
Est. shares
0 shares